PURE Bioscience Announces Approval to List on The NASDAQ Stock Market
SAN DIEGO, CA March 31, 2008 -- PURE Bioscience (OTCBB: PURE) announced today that its application for listing of its common stock has been approved by The NASDAQ Stock Market. PURE Bioscience anticipates that its common stock will begin trading on The NASDAQ Capital Market at the opening of the market on Wednesday April 2, 2008. The stock will trade under the symbol "PURE."
“Returning to the NASDAQ Stock Market has been a primary goal for us this year,” said Michael L. Krall, President and Chief Executive Officer of PURE Bioscience. “We expect NASDAQ’s electronic multiple market maker structure to provide our company with enhanced exposure and liquidity, and afford our investors the best prices, the fastest execution, and the lowest cost per trade. As the world’s largest electronic stock market, NASDAQ promotes innovation and attracts leading growth companies from a diverse group of sectors. PURE Bioscience certainly fits that description, and we look forward to being a part of The NASDAQ Stock Market.”
"We are thrilled that PURE Bioscience has chosen to relist their stock on NASDAQ," said Bob McCooey, Senior Vice President of New Listings and Capital Markets of The NASDAQ OMX Group, Inc. "PURE Bioscience joins the world’s largest exchange company that spans six continents.” We look forward to supporting PURE Bioscience and its shareholders as they make their transition to NASDAQ."
About PURE Bioscience
PURE Bioscience (PURE) develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. PURE’s flagship technology, silver dihydrogen citrate (SDC), is an electrolytically generated source of stabilized ionic silver. A patented new molecular entity, SDC is distinguished from competitors because of its superior efficacy, reduced toxicity and the inability of bacteria to become resistant to it. PURE produces and markets ready-to-use EPA-registered disinfectant products, as well as varying strengths of SDC concentrate as an active ingredient, additive or preservative for inclusion in third-party products. PURE also pursues development programs for SDC as an active pharmaceutical ingredient in a variety of pharmaceutical products. PURE Bioscience, headquartered in
About NASDAQ®
The NASDAQ Stock Market, a national exchange owned and operated by the NASDAQ OMX Group, Inc., is the largest
For more information about NASDAQ, visit the NASDAQ Web site at www.nasdaq.com or the NASDAQ Newsroom(SM) at www.nasdaq.com/newsroom.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
# # #